Psoriatic Arthritis (PsA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Psoriatic Arthritis (PsA) Market Outlook
Thelansis’s “Psoriatic Arthritis (PsA)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Psoriatic Arthritis (PsA) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
Psoriatic
Arthritis (PsA) Overview
Psoriatic
arthritis (PsA) is a chronic autoimmune inflammatory condition primarily
affecting the joints and the areas where tendons and ligaments connect to
bones. It typically co-occurs with a skin condition known as psoriasis.
Enthesitis is among its most common distinguishing features. Other clinical
manifestations include joint swelling, painful and itchy red patches, and the
accumulation of silvery dead skin cells. PsA can also impact the sacroiliac
joint of the pelvic region and the spine, resulting in stiffness in the neck
and back. The precise cause of psoriatic arthritis remains unknown. It usually
emerges in individuals between 30 and 50, although it can begin as early as
childhood. Both genders are equally susceptible to PsA, and its genetic epidemiology
sets it apart. PsA has been linked to human leukocyte antigen (HLA) class 1
allele, compared to rheumatoid arthritis (RA), associated with HLA class 2
alleles. Notably, PsA presents distinct extra-articular manifestations compared
to RA, with the absence of rheumatoid nodules. While rheumatoid factor is
detected in over 80% of RA patients, it is found in only about 13% of
individuals with PsA.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment